enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Lotte Bjerre Knudsen - Wikipedia

   en.wikipedia.org/wiki/Lotte_Bjerre_Knudsen

   Lotte Bjerre Knudsen from Novo Nordisk is a new honorary professor at Health, Aarhus University. She is the person behind the discovery of liraglutide, a new class of drugs for Novo Nordisk that are used in the treatment of type 2 diabetes and obesity.

3. The Hagedorn Prize - Wikipedia

   en.wikipedia.org/wiki/The_Hagedorn_Prize

   The Hagedorn Prize is an annual award within the field of medical research, specifically recognizing outstanding contributions to diabetes research and endocrinology.Named after Hans Christian Hagedorn, a renowned Danish scientist and co-founder of Nordisk Insulinlaboratorium [1] (now part of Novo Nordisk), the prize celebrates achievements in the understanding and treatment of diabetes.

4. Hans Christian Hagedorn - Wikipedia

   en.wikipedia.org/wiki/Hans_Christian_Hagedorn

   Hans Christian Hagedorn (6 March 1888 – 6 October 1971) was the creator of NPH insulin and the founder of Nordisk Insulinlaboratorium, which is known today as Novo Nordisk. Early life and education [ edit ]

5. Comparing Oral vs. Injectable Semaglutide: Is One More ... - AOL

   www.aol.com/comparing-oral-vs-injectable...

   Research sponsored by Novo Nordisk in patients with type 2 diabetes found that, together with diet and exercise, Ozempic led to an average weight loss of almost 10 pounds, while Rybelsus led to an ...

6. This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve ...

   www.aol.com/finance/huge-news-novo-nordisk-hint...

   Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care.. The company develops a long line of blockbuster glucagon-like ...

7. Mads Krogsgaard Thomsen - Wikipedia

   en.wikipedia.org/wiki/Mads_Krogsgaard_Thomsen

   Mads Krogsgaard Thomsen was employed by Novo Nordisk in 1991 as head of Growth Hormone Research and became Executive Vice President for Diabetes R&D in 1994. He was appointed senior vice president of Diabetes R&D in 1994. In November 2000, he was appointed executive vice president and Chief Scientific Officer (CSO). [4]

8. US FDA flags dosing risks from compounded versions of Novo's ...

   www.aol.com/news/us-fda-flags-dosing-risks...

   (Reuters) -The U.S. Food and Drug Administration on Friday warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk's weight-loss and diabetes drugs.

9. Insulin degludec - Wikipedia

   en.wikipedia.org/wiki/Insulin_degludec

   Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. [7] It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes.